Back

Polygenic risk score for prediction of atrial fibrillation according to presence of the hypertrophic cardiomyopathy

2 September 2024 (10:00 - 10:50)
Organised by: Logo
Congress Presentation Part of: Prediction of incident atrial fibrillation: from biomarkers to artificial intelligence Prevalence and Incidence of Atrial Fibrillation ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Boyoung Joung

Yonsei University, Seoul (Korea (Republic of))

6 More presentations in this session

Presentation thumbnail
Impact of changes in proteinuria on the risk of atrial fibrillation in patients with diabetes mellitus: a nationwide population-based study
Doctor H. Rha (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Proteomic and genomic evaluation of plasma protein biomarkers for atrial fibrillation
Mr O. Vad (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Circulating ketone bodies, genetic predisposition, and incident atrial fibrillation
Ms Y. Sun (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Proteinuria and the risk of incident atrial fibrillation according to diabetes stage in patients with diabetes: a nationwide population-based cohort study
Mr M. Yeo (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Artificial intelligence-enabled electrocardiogram for left ventricular diastolic dysfunction and long-term risk of new-onset atrial fibrillation
Doctor G. Tsaban (Rochester, US)
Abstract Slides Video

Access the full session

Session thumbnail
Prediction of incident atrial fibrillation: from biomarkers to artificial intelligence

The Event

Event poster

ESC Congress 2024

2 September 2024 10:00 CET
You may be interested in
thumbnail
Congress Presentation
Markers of atrial myopathy in the UK Biobank: prevalence, consequences, and risk stratification
thumbnail
Congress Presentation
Prevalence and implications of cardiomyopathy-associated genetic variants in early-onset atrial fibrillation
thumbnail
Congress Presentation
REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM trials: Incidence and impact of atrial fibrillation in oHCM with aficamten

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources